Regeneron Pharmaceuticals, Inc. Website

Regeneron Pharmaceuticals, Inc.

NasdaqGS-REGN

Income Statement
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Operating Revenues

6,383.6

7,940.1

15,790.5

11,807.8

12,581.1

12,916.9

Other Revenues, Total

174

557

281.2

365.1

536.1

572.2

Total Revenues

6,557.6

8,497.1

16,071.7

12,172.9

13,117.2

13,489.1

Total Revenues % Chg.

27.4%

29.6%

89.1%

-24.3%

7.8%

6.5%

Cost of Goods Sold, Total

3,215.1

3,766.9

5,297.6

5,152.9

6,254.8

6,303.2

Gross Profit

3,342.5

4,730.2

10,774.1

7,020

6,862.4

7,185.9

Selling General & Admin Expenses, Total

1,341.9

1,346

1,824.9

2,115.9

2,631.3

2,826

R&D Expenses

—

—

—

—

—

—

—

—

—

—

265.1

Other Operating Expenses

—

—

—

—

-209.2

-280.4

-45.6

-89.9

-2.1

28.9

Other Operating Expenses, Total

1,132.7

1,065.6

1,779.3

2,026

2,629.2

3,120

Operating Income

2,209.8

3,664.6

8,994.8

4,994

4,233.2

4,065.9

Interest Expense, Total

-30.2

-56.9

-57.3

-59.4

-73

-67

Interest And Investment Income

—

—

—

—

—

—

75.4

45.8

160.1

495.9

623.3

Net Interest Expenses

-30.2

18.5

-11.5

100.7

422.9

556.3

Currency Exchange Gains (Loss)

—

—

—

—

—

—

—

0.4

50.2

-12.9

-12.9

Other Non Operating Income (Expenses)

131.2

19.3

4

8.8

-20

-15.2

EBT, Excl. Unusual Items

2,310.8

3,702.4

8,987.7

5,153.7

4,623.2

4,594.1

Gain (Loss) On Sale Of Investments

—

—

—

118.3

196

386.1

-39.8

-237.8

154.1

In Process R&D Expenses

—

—

—

—

—

—

-88

-48

-255.1

-186.1

-161

Other Unusual Items

—

—

—

—

—

—

—

—

—

EBT, Incl. Unusual Items

2,429.1

3,810.4

9,325.8

4,858.8

4,199.3

4,587.2

Income Tax Expense

313.3

297.2

1,250.5

520.4

245.7

265.5

Earnings From Continuing Operations

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

4,321.7

Net Income

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

4,321.7

Net Income to Common Incl Extra Items

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

4,321.7

Net Income to Common Excl. Extra Items

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

4,321.7

Total Shares Outstanding

109.1

104

106.6

107

107.1

107.9

Weighted Avg. Shares Outstanding

109.2

107.6

105.7

107.1

106.7

107.2

Weighted Avg. Shares Outstanding Dil

114.6

115.1

112.2

113.5

113.7

114.4

EPS

19.4

32.7

76.4

40.5

37.1

40.3

EPS Diluted

18.5

30.5

72

38.2

34.8

37.8

EBITDA

2,420.1

3,900.5

9,281

5,335.4

4,654.2

4,519.1

Effective Tax Rate

12.9%

7.8%

13.4%

10.7%

5.9%

5.8%